Osteoarthritis and osteoporosis in postmenopausal women: Clinical similarities and differences

Menopause

Volumn 11, Issue 6 I, 2004, Pages 615-621

  Avci, Dilek ^a   Bachmann, Gloria A ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Bisphosphonates; Osteoarthritis; Osteoporosis; Parathyroid hormone; Vitamin D

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; CORTICOSTEROID; ESTROGEN; FOSCARNET; PAMIDRONIC ACID; PARATHYROID HORMONE; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; VITAMIN D; ZOLEDRONIC ACID;

AGE; AGING; BONE DENSITY; BONE RADIOGRAPHY; BONE TURNOVER; DRUG USE; FEMALE; HEALTH PROMOTION; HUMAN; MORBIDITY; MORTALITY; OSTEOARTHRITIS; OSTEOPOROSIS; PATHOPHYSIOLOGY; POSTMENOPAUSE; REVIEW; UNITED STATES; VITAMIN SUPPLEMENTATION;

DIPHOSPHONATES; FEMALE; HUMANS; OSTEOARTHRITIS; OSTEOPOROSIS, POSTMENOPAUSAL; VITAMIN D;

EID: 14844340947     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.GME.0000119985.45613.7E     Document Type: Review

References (65)

1. National Osteoporosis Foundation. Available at: http://www.nof. org/. Accessed June 20, 2003.
2. Felson DT, Lawrence RC, Dieppe PA, et al. Osteoarthritis: new insights: Part 1: the disease and its risk factors. Ann Intern Med 2000;133:635-646.
3. Hinton R, Moody RL, Davis A, Thomas S. Osteoarthritis: Diagnosis and therapeudic considerations. Am Fam Physician 2002;65: 842-848.
4. Lawrence RC, Helmic CG, Arnett FC, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998;41:778-799.
5. Elders MJ. The increasing impact of arthritis on public health. J Rheumatol Suppl 60 2000;27:6-8.
6. Foss MV, Byers PD. Bone density, osteoarthritis of the hip and fracture of the upper end of the femur. Ann Rheum Dis 1972;31:259-264.
7. Dequeker J, Johnell O. Osteoarthritis protects against femoral neck fracture: The MEDOS study experience. Bone 1993;14(Suppl 1):51-56.
8. Hart DJ, Mootoosamy I, Doyle DV, Spector TD. The relationship between osteoarthritis and osteoporosis in the general population: The Chingford Study. Ann Rheum Dis 1994;53:158-162.
9. Stewart A, Black A, Robins SP, Reid DM. Bone density and bone turnover in patients with osteoarthritis and osteoporosis. J Rheumatol 1999;26:622-666.
10. Lethbridge-Cejku M, Tobin JD, Scott WW, et al. Axial and hip bone mineral density and radiographic changes of osteoarthritis of the knee: Data from the Baltimore longitudinal study of aging. J Rheumatol 1996;23:1943-1947.
11. Sowers M, Lachance L, Jamadar D, et al. The associations of bone mineral density and bone turnover markers with osteoarthritis of the hand and knee in pre- and perimenopausal women. Artritis Rheum 1999;42:483-489.
12. Hart DJ, Cronin C, Maxine D, Worthy T, Doyle D, Spector TD. The relationship of bone density and fracture to incident and progressive radiographic osteoarthritis of the knee: The Chingford Study. Artritis Rheum 2002;46:92-99.
13. Glowacki J. Advances in Skeletal Biology. The Harvard Orthopaedic Journal. Available at: http://www.mgh.harvard.edu/depts/ hoj/html/articles.html. Accessed October 10, 2003.
14. Bettice P, Cline G, Hart DJ, Meyer J, Spector TD. Evidence for increased bone resorption in patients with progressive knee osteoarthritis: Longitudinal results from the Chingford Study. Artritis Rheum 2002;46:3178-3184.
15. Zhang Y, Hannan MT, Chaisson CE, et al. Bone mineral density and risk of incident and progressive radiographic knee osteoarthritis in women: The Framingham Study. J Rheumatol 2000;27:1032-1037.
16. Nevitt MC, Cumming SR, Lane NE, et al. Association of estrogen replacement therapy with the risk of osteoarthritis of the hip in elderly white women. Arch Intern Med 1996;156:2073-2080.
17. Spector TD, Nandra D, Hart DJ, Doyle DV. Is hormone replacement therapy protective for hand and knee osteoarthritis in women? The Chingford Study. Ann Rheum Dis 1997;56:432-434.
18. Claassen H, Hornberger F, Scholz-Ahrens K, Schunke M, Schrezenmeir J, Kurz B. The effect of estrogens and dietary calcium deficiency on the extracellular matrix of articular cartilage in Gottingen miniature pigs. Ann Anat 2002;184:141-148.
19. Sandmark H, Hogstedt C, Lewold S, Vingard E. Osteoarthrosis of the knee in men and women in association with overweight, smoking, hormone therapy. Ann Rheum Dis 1999;58:151-155.
20. Von Mulhen D, Morton D, Von Muhlen CA, Barrett-Connor E. Postmenopausal estrogen and increased risk of clinical osteoarthritis at the hip, hand and knee in older women. J Womens Health 2002;11:511-518.
21. Swagerty DL, Hellinger D. Radiographic assessment of osteoarthritis. Am Fam Physician 2001;64:279-286.
22. Lawrence JS, Bremmer JM, Bier F. Osteoarthrosis; Prevalance in the population and relationships between symptoms and x-ray changes. Ann Rheum Dis 1966;25:1-24.
23. Kraus VB. Pathogenesis and treatment of osteoarthritis. Med Clin North Am 1997;81:85-112.
24. DeGroot J, Bank RA, Tchetverikov I, Verzijl N, TeKoppele JM. Molecular markers for osteoarthritis: The road ahead. Curr Opin Rheumatol 2002;14:585-589.
25. Felson DT, Lawrence RC, Hochberg MC, et al. Osteoarthritis: new insights: Part 2: treatment approaches. Ann Intern Med 2000;133: 726-737.
26. Russell RG, Rogers MJ. Bisphosphonates: from the laboratory to the clinic and back again. Bone 1999;25:97-106.
27. Reinhoz GG, Getz B, Pederson L, et al. Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts. Cancer Res 2000;60:6001-6007.
28. Potworny NV, Kandel RA, Renlund RC, Grynpas MD. Partial chondroprotective effect of zoledronate in a rabbit model of inflammatory arthritis. J Rheumatol 1999;26:1972-1982.
29. Myers SL, Brandt KD, Burr DB, O'Connor BL, Albrecht M. Effects of a bisphosphonate on bone histomorphometry and dynamics in the canine cruciate deficiency model of osteoarthritis. J Rheumatol 1999;26:2645-2653.
30. Gray AW, Davies ME, Jeffcott LB. Generation and activity of equine osteoclasts in vitro: Effects of the bisphosphonate pamidronate (APD). Res Vet Sci 2002;72:105-113.
31. Muehleman C, Green J, Williams JM, Kuattner KE, Thonar EJ, Sumner DR. The effect of bone remodeling inhibition by zoledronic acid in an animal model of cartilage matrix damage. Osteoarthritis Cartilage 2002;10:226-233.
32. Van Offel JF, Schuerwegh AJ, Bridts CH, Stevens WJ, De Clerck LS. Effect of bisphosphonates on viability, proliferation, and dexamethasone-induced apoptosis of articular chondrocytes. Ann Rheum Dis 2002;61:925-928.
33. Dodge GR, Poole AR. Immunohistochemical detection and immunochemical analysis of type 11 collagen degradation in human normal, rheumatoid, and osteoarthritic articular cartilages and in explants of bovine articular cartilage cultured with interleukin 1. J Clin Invest 1989;83:647-661.
34. Hollander AP, Heathfield TF, Webber C, et al. Increased damage to type 11 collagen in osteoarthritic articular cartilage detected by new immunoassay. J Clin Invest 1994;93:1722-1732.
35. Hollander AP, Pidoux I, Reiner A, Rorabeck C, Bourne R, Poole AR. Damage to type 11 collagen in aging and osteoarthritis starts at the articular surface, originates around chondrocytes, and extends into the cartilage with progressive degeneration J Clin Invest 1995; 96:2859-2869.
36. Billinghurst RC, Dahlberg L, Ionescu M, et al. Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage. J Clin Invest 1997;99:1534-1545.
37. Stoop R, van der Kraan PM, Buma P, Hollander AP, Poole AR, van den Berg WB. Denaturation of type 11 collagen in articular cartilage in experimental murine arthritis. Evidence for collagen degradation in both reversible and irreversible cartilage damage. J Pathol 1999; 188:329-337.
38. Thibault M, Poole AR, Bushmann MD. Cyclic compression of cartilage/bone explants in vitro leads to physical weakening, mechanical breakdown of collagen and release of matrix fragments. J Orthop Res 2002;20:1265-1273.
39. Garnero P, Christgau S, Delmas PD. The bisphosphonate zoledronate decreases type 11 collagen breakdown in patients with Paget's disease of bone. Bone 2001;28:461-464.
40. D'Lima DD, Hashimoto S, Chen P, Colwell CW, Lotz M. Human chondrocyte apoptosis in response to mechanical injury. Osteoarthritis Cartilage 2001;9:712-719.
41. Kim HT, Lo MY, Pillarisetty R. Chondrocyte apoptosis following intraarticular fracture in humans. Osteoarthritis Cartilage 2002;10: 747-749
42. Aigner T, Hemmel M, Neureiter P, et al. Apoptotic cell death is not a widespread phenomenon in normal aging and osteoarthritis human articular knee cartilage: a study of proliferation, programmed cell death (apoptosis), and viability of chondrocytes in normal and osteoarthritic human knee cartilage. Artritis Rheum 2001;44:1304-1312.
43. Mobasheri A. Role of chondrocyte death and hypocellularity in ageing human articular cartilage and the pathogenesis of osteoarthritis. Med Hypotheses 2002;58:193-197.
44. Yatsugi N, Tsukazaki T, Osaki M, Koji T, Yamashita S, Shindo H. Apoptosis of articular chondrocytes in rheumatoid arthritis and osteoarthritis: correlation of apoptosis with degree of cartilage destruction and expression of apoptosis-related proteins of p53 and cmyc. J Orthop Sci 2000;5:150-156.
45. Mansfield K, Rajpurohrt R, Shapiro JM. Extracellular phosphate ions cause apoptosis of terminally differentiated epiphyseal chondrocytes. J Cell Physiol 1999;179:276-286.
46. Mansfield K, Teixeria CC, Adams S, Shapiro IM. Phosphate ions mediate chondrocyte apoptosis through a plasma membrane transporter mechanism. Bone 2001;28:1-8.
47. Plotkin LI, Weinsteis RS, Parfitt AM, Roberson PK, Manolagas SC, Bellido T. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest 1999;104:1363-1374.
48. LeBoff MS, Kohlmeier L, Hurwitz S, Franklin J, Wright J, Glowacki J. Occult vitamin D deficiency in postmenopausal US women with acute hip fracture. JAMA 1999;281:1505-1511.
49. Bhalla AK, Wojno WC, Goldring MB. Human articular chondrocytes acquire 1,25-(OH)2 vitamin D-3 receptors in culture. Biochim Biophys Acta 1987;931:26-32.
50. McAlindon TE, Felson DT, Zhang Y, et al. Relation of dietary intake and serum levels of vitamin D to progression of osteoarthritis of the knee among participants in the Framingham Study. Ann Intern Med 1996;125:353-359.
51. Lane NE, Gore LR. Cumming SR, et al. Serum vitamin D levels and incident changes of radiographic hip osteoarthritis: A longitudinal study. Artritis Rheum 1999;42:854-860.
52. Hodsman AB. Steer BM. Early histomorphometric changes in response to parathyroid hormone therapy in osteoporosis: evidence for de novo bone formation on quiescent cancellous surfaces. Bone 1993;14:523-527.
53. Nishida S, Yamaguchi A, Tanizawa T, et al. Increased bone formation by intermittent parathyroid hormone administration is due to the stimulation of proliferation and differentiation of osteoprogenitor cells in bone marrow. Bone 1994;15:717-723.
54. Dobnig H, Turner RT. Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells. Endocrinology 1995;136:3632-3638.
55. Jilka RL, Weinstein RS, Bellito T, Robertson P, Parfitt AM, Manolagas SC. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest 1999;104:439-446.
56. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Metab 2001;344:1434-1441.
57. Body JJ, Gaich GA, Scheele WH, et al. A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2002;87:4528-4535.
58. Kato Y, Shimazu A, Nakashima K, Suzuki F, Jikko A, Iwamoto M. Effects of parathyroid hormone and calcitonin on alkaline phosphatase activity and matrix calcification in rabbit growth-plate chondrocyte cultures. Endocrinology 1990;127:114-118.
59. Lee K, Lanske B, Karaplis AC, et al. Parathyroid hormone-related peptide delays terminal differentiation of chondrocytes during endochondral bone development. Endocrinology 1996;137:5109-5118.
60. Shukunami C, Shigeno C, Atsumi T, Ishizeki K, Suzuki F, Hiraki Y. Chondrogenic differentiation of clonal mouse embryonic cell line ATDC5 in vitro: differentiation-dependent gene expression of parathyroid hormone (PTH)/PTH-related peptide receptor. J Cell Biol 1996;133:457-468.
61. Vortkamp A, Lee K, Lanske B, Segre GV, Kronenberg HM, Tabin CJ. Regulation of rate of cartilage differentiation by Indian hedgehog and PTH-related protein. Science 1996;273:613-622.
62. Amizuka N, Warshawsky H, Henderson JE, Goltzman D, Karaplis AC. Parathyroid hormone-related peptide-depleted mice show abnormal epiphyseal cartilage development and altered endochondral bone formation. J Cell Biol. 1994;126:1611-1623.
63. Terkeltaub R, Lotz M, Johnson K, et al. Parathyroid hormone-related proteins is abundant in osteoarthritic cartilage, and the parathyroid hormone-related protein 1-173 isoform is selectively induced by transforming growth factor beta in articular chondrocyles and suppresses generation of extracellular inorganic pyrophosphate. Arthritis Rheum 1998;41:2152-164.
64. Kudo S, Mizuta H, Otsuka Y, Takagi K, Hiraki Y. Inhibition of chondrogenesis by parathyroid hormone in vivo during repair of full-thickness defects of articular cartilage. J Bone Miner Res 2000; 15:253-260.
65. th Annual Meeting; February 25-28, 2001; San Francisco, Calif. Available at: http://www.jbjs. org/ORS_2001/pdfs/0689.pdf. Accessed June 25, 2003.